|
Dr. Natchus has over a decade of experience in medicinal chemistry within the pharmaceutical industry and has a record of excellence and innovation in discovering new medicines. He was the inventor of a novel matrix metallo-protease inhibitor that was ultimately advanced into Phase II clinical evaluation by Procter and Gamble Pharmaceuticals. While there, he also led research teams on projects in the area of kinase inhibition for application in both cancer and inflammation based disorders. Since leaving Procter and Gamble in 2001, Dr. Natchus lead the chemistry and scientific efforts at Somatocor Pharmaceuticals and has been a part of a lecture team for a drug discovery course that has been taught at Emory University and elsewhere including an international presentation in South Africa. Dr. Natchus received his Ph.D. degree in 1991 from Va. Polytechnic Institute and was a postdoctoral fellow at Stanford University under the supervision of Paul Wender. While at Stanford University, he worked on a practical synthetic approach to the anti-cancer drug Taxol that resulted in the most efficient total synthesis of the drug to date.Dr. Natchus has published over thirty scientific papers including three book chapters. He is also a key author on over twenty-five patent applications, many of which have issued in the U.S. and other countries throughout the world. He has lectured extensively including several invited lectures in the U.S. and abroad. | 